Výsledky vyhledávání - "Kuniomi Matsuura"

The Macroscopic Appearance of Computed Tomography-guided Needle Biopsy Specimens Correlates with Tumor Metastasis in Non-small Cell Lung Cancer

Autor: Nakai, Toshiyuki, Tatsuo, Kimura, Tomohiro, Suzumura, Naoki, Yoshimoto, Takako, Oka, Norio, Yamamoto, Kuniomi, Matsuura, Shigeki, Mitsuoka, Kazuhisa, Asai, Yoshihiro, Tochino, Naruo, Yoshimura, Tomoya, Kawaguchi, Shinzoh, Kudoh, Toshiyuki, Matsuoka, Masahiko, Ohsawa, Kazuto, Hirata

Publikováno v: Osaka city medical journal. 61(2)

Computed tomography (CT)-guided needle biopsy is a well-established and dependable procedure for the diagnosis of pulmonary lesions. Some tissue biopsy samples have loose cohesion and disintegrate into tiny pieces before formalin fixation. The purpos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f9712b5dceceb38e30e7953dfa49fdd0
https://pubmed.ncbi.nlm.nih.gov/26995854

Zobrazit plný text záznamu

Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR

Autor: Shun-ichi Isa, Takako Oka, Akihito Kubo, Hidenori Tanaka, Shinzoh Kudoh, Kazuhisa Asai, Kazuto Hirata, Tatsuo Kimura, Kuniomi Matsuura, Tomoya Kawaguchi, Kenji Sawa, Tetsuya Watanabe, Naruo Yoshimura, Shigeki Mitsuoka, Naoki Yoshimoto, Toshiyuki Nakai, Tomohiro Suzumura, Masato Uji

Publikováno v: Expert opinion on pharmacotherapy. 17(2)

While epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) lead to longer progression-free survival (PFS) when compared with conventional chemotherapy in non-small-cell lung cancer (NSCLC) harboring activating EGFR mutations, t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f07a7ee3d9631c64fa0d9b16e029fe4
https://pubmed.ncbi.nlm.nih.gov/26781399

Zobrazit plný text záznamu

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

Autor: Kazuto Hirata, Tatsuo Kimura, Kuniomi Matsuura, Kazuhiko Nakagawa, Kaoru Matsui, Shinzoh Kudoh, Shigeki Mitsuoka, Naruo Yoshimura, Shunichi Negoro, Masahiro Fukuoka

Publikováno v: Lung Cancer. 51:363-368

EKB-569 is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent. A phase 1, dose-escalation study was conducted in Japanese patients. EKB-569 w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06153ba6a707dd754c35051428990539
https://doi.org/10.1016/j.lungcan.2005.10.006

Zobrazit plný text záznamu

Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study

Autor: Norio Yamamoto, Shinzoh Kudoh, Kuniomi Matsuura, Shigeki Mitsuoka, Tomohiro Suzumura, Naoki Yoshimoto, Kazuto Hirata, Tatsuo Kimura, Naruo Yoshimura, Toshiyuki Nakai, Takako Oka

Publikováno v: BMC Pharmacology & Toxicology

Background Renal toxicity is a clinical problem that affects 28 − 42% of patients undergoing treatment with cisplatin. Renal toxicity can be minimized by high volume hydration with mannitol diuresis. Recent reports have shown that cisplatin induces

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2303ad5adfd33f79bfa9672e98cb07ba
https://pubmed.ncbi.nlm.nih.gov/25472655

Zobrazit plný text záznamu

Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs

Autor: Kanako, Umekawa, Tatsuo, Kimura, Shinzoh, Kudoh, Tomohiro, Suzumura, Misato, Nagata, Shigeki, Mitsuoka, Kuniomi, Matsuura, Takako, Oka, Naruo, Yoshimura, Yukimi, Kira, Kazuto, Hirata

Publikováno v: Osaka city medical journal. 59(1)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are routinely used to treat advanced non-small cell lung cancer (NSCLC) patients with activated EGFR mutations, and are associated with excellent response and improvement of pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a25809e3c479fb0655592d07b51093b3
https://pubmed.ncbi.nlm.nih.gov/23909081

Zobrazit plný text záznamu

Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs

Autor: Naruo Yoshimura, Shinzoh Kudoh, Tomohiro Suzumura, Kanako Umekawa, Kuniomi Matsuura, Shigeki Mitsuoka, Kazuto Hirata, Yukimi Kira, Tatsuo Kimura, Misato Nagata, Toshiyuki Nakai, Takako Oka

Publikováno v: BMC Research Notes

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), routinely used to treat advanced non-small-cell lung cancer (NSCLC) patients with activated EGFR mutations, are associated with excellent response and improved perf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9677e6549dbae610cdeeefb124bf24b9
https://doi.org/10.1186/1756-0500-6-139

Zobrazit plný text záznamu

Smoking history and prior surgical resection predict sensitivity to gefitinib in advanced non-small-cell lung cancer

Autor: Kuniomi, Matsuura, Shinzoh, Kudoh, Naruo, Yoshimura, Tatsuo, Kimura, Shigeki, Mitsuoka, Kazuto, Hirata, Junichi, Yoshikawa, Hiroshi, Iwao

Publikováno v: Osaka city medical journal. 52(1)

Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase, and induces radiographic regression and symptomatic improvement in patients with non-small cell lung cancer (NSCLC). Phase II trials suggested female sex and adenocarcinom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e65659273afa25a87114585c95af7da4
https://pubmed.ncbi.nlm.nih.gov/16986358

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání